Molecular Mechanisms of Steroid-Induced Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$69,334
Active Dates
April 01, 2004 - September 30, 2006
Grant ID
G2004018
Summary
Steroid medications are widely used to treat many inflammatory conditions. However, there can be undesirable side effects of steroid use, especially when they are used long-term. One of the side effects in the eye is the development of increased eye pressure, which can lead to glaucoma and, ultimately, vision loss. Approximately one out of every three normal people is at risk of developing steroid-induced glaucoma. Using donor eyes, Dr. Kwon and his team are comparing the differences between people who develop steroid-induced glaucoma and those who do not. It is already known that steroids influence which genes are turned on and off in the body’s cells, including the drainage area of the eye called the trabecular meshwork. Dr. Kwon’s research will help scientists understand why the pressure in the eye is maintained at a constant level in some people, and what goes wrong in the eyes of those who react to steroids with an elevation of eye pressure. It is hoped that this information will be helpful in finding treatments that avoid steroid-induced glaucoma, allowing the safer use of steroids in patients with ocular inflammation.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute